Watson Biotech: 2025 Annual Performance Preview
Securities code: 300142 Securities abbreviation: Watson Biotechnology Announcement number: 2026-014
Yunnan Watson Biotechnology Co., Ltd.
2025 Annual Performance Forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Performance forecast for this period
Performance forecast period: January 1, 2025 to December 31, 2025.
Performance forecast situation: voluntary performance forecast
(1) Performance forecast based on interval numbers
Unit: 10,000 yuan
Item This fiscal year Shares attributable to listed companies in the same period last year 16,000 ~ 19,000
The net profit of RMB 14,216.04 increased by 13.00% to 34.00% over the same period last year.
Excluding non-recurring gains and losses 8,500 ~ 9,900
Net profit after 10,839.61 decreased by 22.00% ~ 9.00% compared with the same period last year
Operating income 240,000 ~ 243,000 282,144.13
2. Communication with the accounting firm
The data related to the current performance forecast are the results of preliminary calculations by the Finance Department of Yunnan Watson Biotechnology Co., Ltd. (hereinafter referred to as the "Company") and have not been audited by an audit agency. However, the company has pre-communicated with the audit agency on matters related to the performance forecast. There is no disagreement between the company and the audit agency regarding the matters related to this performance forecast.
3. Explanation of reasons for performance changes
The main factors affecting changes in performance in 2025 are as follows:
During the reporting period, the domestic and foreign vaccine markets were generally still in a downward cycle, and the company's total vaccine product revenue fell by approximately 8% compared with the same period last year. The company's revenue from domestic vaccine products has narrowed and stabilized, revenue from foreign vaccine products has continued to grow, and revenue from exported vaccine products has increased by approximately 35% compared with the same period last year. The company has continued to strengthen a series of control measures such as cost reduction and efficiency improvement, and its operational management capabilities have continued to improve. The company has comprehensively achieved an increase in net profit attributable to shareholders of listed companies during the reporting period compared with the same period last year.
During the reporting period, the company's non-recurring profits and losses were approximately RMB 80 million, compared with RMB 33.76 million in the same period last year.
4. Other related instructions
The data related to this performance forecast are the preliminary calculation results of the company's finance department. The specific financial data will be disclosed in detail in the 2025 annual report. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Yunnan Watson Biotechnology Co., Ltd.
January 28, 2026